📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
0 analysed today
FollowTelegram
0
Today
152,139
All-time analysed
43,645
Positive
6,747
Negative
92,898
Neutral
8,781
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
100 announcements match the current filters (relevance ≥ 5).
India Pesticides FY26 Revenue Crosses ₹1,000 Cr Milestone; PAT Surges 45.8% YoY to ₹120 Cr
India Pesticides Limited (IPL) delivered a robust performance for FY2026, with annual revenue crossing the ₹1,000 crore mark for the first time to reach ₹1,078 crore, a 27.9% YoY growth. Profitability improved significantly as EBITDA rose 44.7% to ₹194 crore, with margins expanding from 15.9% to 18.0%. Net profit for the year grew by 45.8% to ₹120 crore, supported by strong domestic demand and volume growth. The company continues its expansion at the Hamirpur facility, with two blocks currently operational and two more expected to be commissioned in FY2027.
Key Highlights
Annual Revenue reached ₹1,078 Cr, crossing the ₹1,000 Cr milestone with 27.9% YoY growth.
FY26 EBITDA increased by 44.7% to ₹194 Cr, with EBITDA margins expanding to 18.0%.
Full-year PAT grew by 45.8% YoY to ₹120 Cr, while Q4 FY26 PAT rose 40.6% to ₹31 Cr.
Technicals and APIs contributed 71% of total revenue, while exports accounted for 39% of the mix.
Maintained a healthy balance sheet with a Debt/Equity ratio of 0.1x and ROCE of 16.8%.
👀 What to Watch
Investors should note the significant scale-up in operations and margin expansion, which indicates strong execution and pricing power. The ongoing capacity expansion at Hamirpur provides a clear visibility for future volume-led growth.
India Pesticides Recommends ₹0.75 Dividend; Sets AGM for August 31, 2026
India Pesticides Limited (IPL) has recommended a dividend of ₹0.75 per equity share of face value ₹1 for the financial year ended March 31, 2026. The company has fixed August 24, 2026, as the record date to determine shareholder eligibility for the payout. The 41st Annual General Meeting (AGM) is scheduled to be held on August 31, 2026, via video conferencing. Furthermore, the board approved the audited financial results for FY26, which received an unmodified audit opinion from the statutory auditors.
Key Highlights
Recommended a final dividend of ₹0.75 per equity share (75% of face value) for FY 2025-26.
Fixed August 24, 2026, as the record date for dividend eligibility.
The 41st Annual General Meeting is scheduled for August 31, 2026.
Statutory auditors issued an unmodified (clean) audit opinion on standalone and consolidated results.
Re-appointed M/s Seth & Associates as Internal Auditors and M/s Honey Singh & Associates as Cost Auditors for FY 2026-27.
👀 What to Watch
Investors interested in the dividend should ensure they hold shares before the record date of August 24, 2026. The clean audit report is a positive sign regarding the company's financial transparency and reporting integrity.
India Pesticides Recommends ₹0.75 Dividend; Sets Record Date for August 24, 2026
India Pesticides Limited has recommended a dividend of ₹0.75 per equity share of face value ₹1 for the financial year ended March 31, 2026. The company has fixed August 24, 2026, as the record date to determine the eligibility of shareholders for this payment. The dividend is subject to approval by members at the 41st Annual General Meeting scheduled for August 31, 2026. Additionally, the board approved the audited financial results for FY26 with an unmodified audit opinion from the statutory auditors.
Key Highlights
Recommended dividend of ₹0.75 per equity share (75% of face value)
Record date for dividend eligibility set as August 24, 2026
41st Annual General Meeting (AGM) scheduled for August 31, 2026
Re-appointment of Internal and Cost Auditors for the Financial Year 2026-27
Audited financial results for FY26 approved with an unmodified audit opinion
👀 What to Watch
Investors interested in the dividend should ensure they hold the stock prior to the ex-dividend date. Shareholders should also review the full FY26 audited results to evaluate the company's annual performance and operational efficiency.
India Pesticides Recommends Rs 0.75 Final Dividend; Sets Record Date for Aug 24
India Pesticides Limited (IPL) has announced a final dividend of Rs 0.75 per equity share for the financial year ended March 31, 2026. The board has fixed August 24, 2026, as the record date to determine shareholder eligibility for the payout. Alongside the dividend, the company approved its audited financial results for FY26, which received an unmodified audit opinion from statutory auditors. The dividend remains subject to shareholder approval at the 41st Annual General Meeting scheduled for August 31, 2026.
Key Highlights
Recommended a final dividend of Rs 0.75 per equity share of face value Rs 1 each.
Fixed Monday, August 24, 2026, as the record date for dividend eligibility.
Approved audited standalone and consolidated financial results for the year ended March 31, 2026.
Re-appointed Seth & Associates as Internal Auditors and Honey Singh & Associates as Cost Auditors for FY 2026-27.
41st Annual General Meeting (AGM) to be held on August 31, 2026, via video conferencing.
👀 What to Watch
Investors interested in the dividend should ensure they hold the stock prior to the record date of August 24, 2026. It is also advisable to review the full audited financial results to evaluate the company's year-on-year growth and margin stability.
India Pesticides Q4 & FY26 Results: Board Recommends ₹0.75 Dividend per Share
India Pesticides Limited (IPL) has approved its audited financial results for the quarter and financial year ended March 31, 2026. The Board has recommended a final dividend of ₹0.75 per equity share, representing 75% of the face value. The company's statutory auditors have issued an unmodified audit opinion, indicating a clean bill of health for the financial statements. Additionally, the company has re-appointed its internal and cost auditors for the 2026-27 fiscal year.
Key Highlights
Recommended a final dividend of ₹0.75 per equity share of face value ₹1 for FY 2025-26.
Set Monday, August 24, 2026, as the Record Date for dividend eligibility.
Statutory auditors issued an unmodified audit opinion on both standalone and consolidated results.
Re-appointed M/s Seth & Associates as Internal Auditors and M/s Honey Singh & Associates as Cost Auditors for FY 2026-27.
The 41st Annual General Meeting (AGM) is scheduled for August 31, 2026.
👀 What to Watch
Investors should review the detailed financial statements for margin trends and top-line growth. Existing shareholders must hold the stock until the August 24 record date to be eligible for the ₹0.75 dividend.
Jinkushal Industries Announces Leadership Transition; Abhinav Jain Appointed Managing Director
Jinkushal Industries Limited has announced a strategic leadership reshuffle effective May 16, 2026. Mr. Anil Kumar Jain, who has over 37 years of industry experience, will transition from Managing Director to Chairman cum Executive Director to provide strategic oversight. Mr. Abhinav Jain, previously a Whole-Time Director with 7 years of experience in export and market development, has been appointed as the Managing Director for a five-year term. This transition appears to be a planned succession within the promoter family to drive the company's next phase of global expansion.
Key Highlights
Mr. Abhinav Jain appointed as Managing Director for a 5-year term effective May 16, 2026
Mr. Anil Kumar Jain re-designated as Chairman cum Executive Director to focus on governance and strategic guidance
Abhinav Jain brings 7+ years of experience and was awarded 'Business Leader of the Year (2023)' by CEO Insights
Anil Kumar Jain retains a leadership role with over 37 years of experience in automotive, logistics, and mining sectors
The appointments are subject to shareholder approval at the upcoming General Meeting
👀 What to Watch
Investors should monitor the company's operational performance under the new Managing Director to see if the focus on global expansion translates into revenue growth. No immediate portfolio changes are recommended as this is a structured leadership transition within the promoter group.
Cipla Q4 FY26 Revenue Reaches ₹6,541 Cr; One India Business Grows 15% YoY
Cipla reported a robust Q4 FY26 with revenue of ₹6,541 crores and full-year revenue of ₹28,163 crores. The One India business led growth at 15% YoY, while the North America segment achieved $780 million in annual revenue. EBITDA margins for the year remained healthy at 21%, supported by a 66% gross margin. The company is pivoting towards complex generics and biosimilars, with 40-50 new filings targeted over the next three years.
Key Highlights
One India business grew 15% YoY in Q4; Foracort brand surpassed ₹1,000 crore in annual revenue.
North America annual revenue reached $780 million with the first generic Ventolin approval from a U.S. facility.
Full-year EBITDA margin stood at 21% with a PAT of ₹3,879 crores and ROIC of 22.9%.
R&D spend for FY26 was ₹1,974 crores (7% of revenue) focusing on peptides and biosimilars.
EMEU operations scaled to become a $400 million-plus business unit despite geopolitical challenges.
👀 What to Watch
Maintain a positive outlook given the strong domestic chronic portfolio and the strategic shift toward complex generics in the U.S. Watch for the commercial launch of the 4 respiratory assets planned for FY27.
Cipla Appoints Sushrut Kulkarni as Global IPD Chief; Grants 7.7 Lakh ESOPs and ESARs
Cipla has announced the appointment of Sushrut Kulkarni as President & Global Chief of Integrated Product Development (IPD), effective May 18, 2026. Mr. Kulkarni brings over 30 years of experience, having previously served as Global Head of IPDO at Dr. Reddy's Laboratories. The Board also approved the grant of 1,76,389 stock options and 5,96,244 Employee Stock Appreciation Rights (ESARs) at a nominal exercise price of INR 2. Additionally, the company's 90th Annual General Meeting is scheduled for June 25, 2026.
Key Highlights
Appointment of Sushrut Kulkarni (ex-Dr. Reddy's) as Global Chief of Integrated Product Development
Grant of 1,76,389 stock options under ESOS 2013-A and 5,96,244 ESARs under ESAR 2021
Exercise price for both options and ESARs set at a nominal INR 2 per share
90th Annual General Meeting (AGM) to be convened on June 25, 2026
Appointment of M/s Joshi Apte & Associates as Cost Auditors for FY 2026-27
👀 What to Watch
Investors should view the hiring of a seasoned R&D leader from a major competitor as a positive step for Cipla's product pipeline. Monitor the upcoming AGM for further strategic updates and long-term growth guidance.
Cipla Appoints Sushrut Kulkarni as Global Chief-IPD and Approves 7.7 Lakh ESOPs/ESARs
Cipla has appointed Sushrut Kulkarni, formerly the Global Head of IPDO at Dr. Reddy's Laboratories, as President & Global Chief – Integrated Product Development (IPD) effective May 18, 2026. The Board also approved the grant of 1,76,389 stock options and 5,96,244 Employee Stock Appreciation Rights (ESARs) at an exercise price of INR 2 per share. Additionally, M/s Joshi Apte & Associates were appointed as Cost Auditors for the 2026-27 fiscal year. The company's 90th Annual General Meeting is scheduled to be held on June 25, 2026.
Key Highlights
Appointment of Sushrut Kulkarni (ex-Dr. Reddy's) as Global Chief – Integrated Product Development
Grant of 1,76,389 stock options under ESOS 2013-A with an exercise price of INR 2
Grant of 5,96,244 ESARs under ESAR 2021 with an exercise price of INR 2
90th Annual General Meeting (AGM) scheduled for June 25, 2026
Appointment of M/s Joshi Apte & Associates as Cost Auditors for FY 2026-27
👀 What to Watch
The hiring of a high-profile R&D leader from a major competitor is a positive signal for Cipla's long-term product pipeline. Investors should look for strategic commentary during the upcoming AGM on June 25.
Cipla Appoints Sushrut Kulkarni as Global Chief of IPD; Grants 7.7 Lakh Stock Options/ESARs
Cipla has appointed Sushrut Kulkarni, formerly of Dr. Reddy's Laboratories, as President & Global Chief of Integrated Product Development (IPD) effective May 18, 2026. The company also approved the grant of 1,76,389 stock options and 5,96,244 Employee Stock Appreciation Rights (ESARs) to employees at a nominal exercise price of INR 2. Additionally, the 90th Annual General Meeting is scheduled for June 25, 2026. This leadership change brings over three decades of experience in R&D and regulated markets to Cipla's management council.
Key Highlights
Appointment of Sushrut Kulkarni as President & Global Chief – IPD effective May 18, 2026
Grant of 1,76,389 stock options and 5,96,244 ESARs with an exercise price of INR 2
90th Annual General Meeting (AGM) scheduled for June 25, 2026
Mr. Kulkarni joins from Dr. Reddy's Laboratories where he led the IPD organization
M/s Joshi Apte & Associates appointed as Cost Auditors for the financial year 2026-27
👀 What to Watch
The addition of a seasoned R&D leader from a major competitor is a positive signal for Cipla's future product pipeline and regulated market strategy. Investors should maintain their positions and monitor the upcoming AGM for further strategic updates.
Cipla Appoints Sushrut Kulkarni as Global IPD Chief; Grants 7.7 Lakh Stock Options/ESARs
Cipla has appointed Sushrut Kulkarni, a veteran from Dr. Reddy's Laboratories, as President & Global Chief of Integrated Product Development (IPD) to lead its R&D and product pipeline. The board also approved the grant of 176,389 stock options and 596,244 employee stock appreciation rights (ESARs) at a nominal exercise price of INR 2. Additionally, the company's 90th Annual General Meeting is scheduled for June 25, 2026. These moves indicate a focus on strengthening leadership and talent retention to drive growth in regulated markets.
Key Highlights
Sushrut Kulkarni appointed as Global Chief – Integrated Product Development effective May 18, 2026.
Grant of 176,389 stock options and 596,244 ESARs with an exercise price of INR 2 per share.
90th Annual General Meeting (AGM) convened for June 25, 2026.
M/s Joshi Apte & Associates appointed as Cost Auditors for the financial year 2026-27.
👀 What to Watch
The appointment of a seasoned R&D leader from a major competitor is a positive signal for Cipla's future product pipeline. Investors should monitor the company's progress in complex generic filings under the new leadership.
Cipla FY26 Revenue Hits Record INR 28,163 Cr; EBITDA Margins Contract to 21%
Cipla achieved its highest-ever annual revenue of INR 28,163 Cr in FY26, supported by double-digit growth in the India and North America segments. Despite the revenue growth, EBITDA margins contracted to 21.0% from 25.9% in FY25, and PAT declined to INR 3,879 Cr from INR 5,273 Cr. The company maintains a very strong balance sheet with a net cash position exceeding $1 billion (INR 11,140 Cr). Key strategic milestones include the approval of the first AB-rated gVentolin in the US and crossing the $400 Mn benchmark in North American quarterly revenue.
Key Highlights
Annual revenue reached a record INR 28,163 Cr, with the One India business contributing 45% of total sales.
FY26 EBITDA stood at INR 5,925 Cr with a margin of 21.0%, a decrease from the 25.9% margin reported in FY25.
North America revenue grew 14% YoY in Q4 to $155 Mn, aided by the approval of gVentolin with CGT status.
R&D investment for FY26 was INR 1,974 Cr, accounting for 7.0% of total revenue to support a complex generic pipeline.
Net cash position strengthened to INR 11,140 Cr, providing significant capital for potential M&A and expansion.
👀 What to Watch
Investors should monitor the margin recovery trajectory and the commercial launch of gVentolin in the US. While revenue growth is robust, the year-on-year decline in profitability suggests cost pressures that need to be managed.
Cipla Q4 FY26 PAT Declines to ₹555 Cr; Board Recommends ₹13 Dividend
Cipla reported a weak Q4 FY26 with consolidated PAT falling significantly to ₹555 Cr from ₹1,222 Cr in the previous year. While the One-India business grew by a robust 15% YoY, the North America segment faced a 26% revenue decline during the quarter. Despite quarterly headwinds, the company achieved its highest-ever annual revenue of ₹28,163 Cr for the full year FY26. The company maintains a strong net cash position of ₹10,526 Cr and has proposed a final dividend of ₹13 per share.
Key Highlights
Q4 FY26 PAT stood at ₹555 Cr, down from ₹1,222 Cr in Q4 FY25, with EBITDA margins contracting to 15.2%.
One-India business grew 15% YoY in Q4, driven by double-digit growth across prescription, generics, and consumer health.
North America revenue declined 26% YoY to ₹1,414 Cr in Q4, though it secured approval for the first AB-rated gVentolin.
Full-year FY26 revenue reached a record ₹28,163 Cr with an annual EBITDA margin of 21.0%.
Board recommended a final dividend of ₹13 per equity share (650% of face value).
👀 What to Watch
Investors should monitor the reasons behind the sharp margin contraction and North American revenue decline in Q4. While the India business remains a strong growth engine, the quarterly earnings miss may lead to short-term price volatility.
Cipla Reports FY26 Net Profit of ₹3,879 Cr, Recommends ₹13 Dividend
Cipla's FY26 consolidated revenue grew slightly to ₹28,162.59 crore, but net profit attributable to owners dropped 26.4% YoY to ₹3,879.23 crore. The bottom line was weighed down by an exceptional loss of ₹275.91 crore and significantly lower quarterly performance in Q4. Despite the profit dip, the board recommended a final dividend of ₹13 per share (650% of face value). The record date for the dividend is fixed as June 5, 2026, subject to shareholder approval.
Key Highlights
Recommended final dividend of ₹13 per equity share for FY26; Record date is June 5, 2026.
FY26 Consolidated Revenue increased to ₹28,162.59 crore from ₹27,547.62 crore in FY25.
FY26 Net Profit (Owners) declined to ₹3,879.23 crore from ₹5,272.52 crore in the previous year.
Q4 FY26 Net Profit fell sharply to ₹554.64 crore compared to ₹1,221.84 crore in Q4 FY25.
Reported an exceptional loss of ₹275.91 crore during the financial year ended March 31, 2026.
👀 What to Watch
The significant drop in both quarterly and annual profits is a concern; investors should wait for management commentary on the exceptional loss and margin pressures. The ₹13 dividend offers a steady payout, but the stock may face short-term pressure due to the earnings miss.
Cipla Recommends Rs 13 Dividend; FY26 Net Profit Declines to Rs 3,862 Crore
Cipla's Board has recommended a final dividend of Rs 13 per share for FY26, with a record date of June 5, 2026. The company reported a consolidated revenue of Rs 28,162.59 crore for the full year, representing a marginal growth over the previous year. However, net profit for FY26 saw a significant decline to Rs 3,861.74 crore from Rs 5,269.20 crore in FY25, primarily due to rising expenses and an exceptional loss. The Q4 FY26 performance was particularly weak, with net profit dropping over 50% year-on-year to Rs 542.51 crore.
Key Highlights
Recommended final dividend of Rs 13 per equity share for the financial year ended March 31, 2026.
FY26 Consolidated Revenue from operations stood at Rs 28,162.59 Cr, up from Rs 27,547.62 Cr in FY25.
Full-year Net Profit attributable to owners fell to Rs 3,879.23 Cr compared to Rs 5,272.52 Cr in the previous year.
Q4 FY26 Net Profit plummeted to Rs 542.51 Cr from Rs 1,214.14 Cr in Q4 FY25.
Total expenses for the full year increased to Rs 23,545.06 Cr from Rs 21,588.68 Cr in FY25.
👀 What to Watch
Investors should exercise caution as the sharp decline in profitability and quarterly margins outweighs the dividend announcement. It is advisable to wait for management's clarification on the exceptional items and cost pressures before increasing exposure.
Cipla Q4 Net Profit Drops 55% to ₹542 Cr; Board Recommends ₹13 Dividend
Cipla reported a sharp decline in consolidated net profit for Q4 FY26, falling to ₹542.51 crore from ₹1,214.14 crore in the previous year's corresponding quarter. Total revenue for the quarter also saw a marginal decline to ₹6,541.20 crore compared to ₹6,729.69 crore in Q4 FY25. For the full financial year 2025-26, the company recorded a revenue of ₹28,162.59 crore, while net profit stood at ₹3,861.74 crore, significantly lower than the ₹5,269.20 crore reported in FY25. Despite the earnings pressure, the board has recommended a final dividend of ₹13 per equity share.
Key Highlights
Q4 FY26 consolidated net profit fell 55.3% YoY to ₹542.51 crore from ₹1,214.14 crore.
Full-year FY26 revenue grew marginally by 2.2% to ₹28,162.59 crore.
Board recommended a final dividend of ₹13 per equity share for FY26.
Earnings were impacted by an exceptional loss of ₹275.91 crore during the fiscal year.
Cash and cash equivalents improved to ₹1,015.39 crore as of March 31, 2026, compared to ₹542.65 crore in the previous year.
👀 What to Watch
Investors should exercise caution due to the significant contraction in quarterly profits and the impact of exceptional items. Monitor management's commentary regarding the exceptional loss and margin outlook for the next fiscal year.
Cipla Receives USFDA Approval for First Generic Ventolin® HFA; Market Size ~$1.5 Billion
Cipla has received final USFDA approval for the first AB-rated generic version of Ventolin® HFA, targeting a U.S. albuterol market valued at approximately $1.5 billion. The product, Albuterol Sulfate Inhalation Aerosol, is scheduled for launch in the first half of FY 2026-27. This approval reinforces Cipla's leadership in the complex respiratory segment, where it already holds a significant market share. Manufacturing will be conducted at the company's dedicated inhalation facility in Fall River, Massachusetts, enhancing its domestic U.S. manufacturing footprint.
Key Highlights
First AB-rated generic therapeutic equivalent of Ventolin® HFA approved by USFDA
Targets a total U.S. albuterol market opportunity of approximately $1.5 billion
Commercial launch planned for H1 FY 2026-27 from the Fall River, Massachusetts facility
Strengthens Cipla's position as the 3rd largest player in the US Gx (Repulses + MDI) category
Vertically integrated inhalation platform used to ensure supply resilience and quality
👀 What to Watch
This approval is a significant milestone in Cipla's complex generics strategy and should be viewed as a long-term revenue driver for its U.S. business. Investors should monitor the ramp-up in market share and potential margin expansion following the H1 FY27 launch.
Cipla Receives 2 USFDA Observations for Goa Manufacturing Facility
The USFDA conducted a routine cGMP and Pre-Approval Inspection at Cipla's Verna, Goa facility from April 6 to April 17, 2026. The inspection concluded with the issuance of two observations in Form 483. Cipla has committed to addressing these observations comprehensively within the stipulated timeframe. While observations are a standard part of the regulatory process, the nature of these findings will determine future product approvals from this site.
Key Highlights
USFDA inspection conducted at Verna, Goa facility from April 6 to April 17, 2026
Company received 2 inspectional observations in Form 483
Inspection covered routine cGMP and Pre-Approval Inspection (PAI) protocols
Cipla committed to addressing observations within the stipulated time
👀 What to Watch
Monitor the company's response and the USFDA's final classification of the facility. Since there are only two observations, the risk of a Warning Letter is typically lower, but clarity on the severity is needed.
Cipla MD & CEO Umang Vohra to Step Down; Achin Gupta to Take Charge from April 2026
Cipla has announced a major leadership transition as Mr. Umang Vohra will conclude his 10-year tenure as Managing Director and Global CEO on March 31, 2026. Mr. Achin Gupta is set to take over the leadership role, supported by a newly designated senior management team including Saurabh Gambhir (Strategy & M&A) and Satyavan Manikani (Global Portfolio). The transition appears well-planned with a long lead time, ensuring stability in the company's strategic direction. This change marks the end of a significant era of growth and digital transformation under Vohra's leadership.
Key Highlights
Mr. Umang Vohra to resign as MD & CEO effective April 1, 2026, after completing a 10-year tenure.
Mr. Achin Gupta to be appointed as the new Managing Director and Global Chief Executive Officer.
Two key executives, Saurabh Gambhir and Satyavan Manikani, elevated to Senior Management Personnel (SMP) status.
The leadership change follows the completion of Vohra's current term and his decision not to seek re-appointment.
Transition includes a focus on Strategy, M&A, and Global Portfolio management under the new CEO's direct reports.
👀 What to Watch
Investors should maintain a neutral stance as the transition is planned well in advance, minimizing immediate disruption. Monitor for any shifts in long-term strategy or capital allocation priorities once Achin Gupta officially takes charge in 2026.
Cipla Announces Leadership Transition: Umang Vohra Resigns, Achin Gupta to Take Charge as CEO
Cipla Limited has announced a major leadership transition as Mr. Umang Vohra concludes his tenure as Managing Director and Global CEO on March 31, 2026, after 10 years with the company. Mr. Achin Gupta will assume the role of MD and Global CEO effective April 1, 2026. To support the new leadership, the company has elevated Mr. Saurabh Gambhir (Head of Strategy and M&A) and Mr. Satyavan Manikani (Chief Portfolio Head) to Senior Management Personnel. This planned succession aims to maintain strategic continuity across Cipla's global operations.
Key Highlights
Mr. Umang Vohra resigns as Director and MD & Global CEO effective April 1, 2026, following the completion of his term.
Mr. Achin Gupta to take charge as the new Managing Director and Global Chief Executive Officer.
Two new Senior Management Personnel (SMP) appointments: Mr. Saurabh Gambhir and Mr. Satyavan Manikani, effective April 1, 2026.
Mr. Saurabh Gambhir brings experience from Emcure and Intas, focusing on global M&A and digital transformation.
Mr. Satyavan Manikani, with the company since 2022, will lead global portfolio initiatives and domestic therapy priorities.
👀 What to Watch
Investors should monitor the transition for any shifts in strategic direction, particularly regarding US FDA compliance and capital allocation for M&A. While the transition appears planned, the execution under the new CEO will be a key performance driver for the stock.
